SEARCH

SEARCH BY CITATION

References

  • Alinari, L., Lapalombella, R., Andritsos, L., Baiocchi, R.A., Lin, T.S. & Byrd, J.C. (2007) Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene, 26, 36443653.
  • Bindon, C.I., Hale, G. & Waldmann, H. (1988) Importance of antigen-specificity for complement-mediated lysis by monoclonal-antibodies. European Journal of Immunology, 18, 15071514.
  • Dearden, C.E. & Matutes, E. (2006) Alemtuzumab in T-cell lymphoproliferative disorders. Best practice & research. Clinical haematology, 19, 795810.
  • Dearden, C.E., Matutes, E., Cazin, B., Tjonnfjord, G.E., Parreira, A., Nomdedeu, B., Leoni, P., Clark, F.J., Radia, D., Rassam, S.M.B., Roques, T., Ketterer, N., Brito-Babapulle, V., Dyer, M.J.S. & Catovsky, D. (2001) High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood, 98, 17211726.
  • Dearden, C., Matutes, E. & Catovsky, D. (2002) Alemtuzumab in T-cell malignancies. Medical Oncology, 19(Suppl.), S27S32.
  • Enblad, G., Hagberg, H., Erlanson, M., Lundin, J., MacDonald, A.P., Repp, R., Schetelig, J., Seipelt, G. & Osterborg, A. (2004) A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood, 103, 29202924.
  • Faulkner, R.D., Craddock, C., Byrne, J.L., Mahendra, P., Haynes, A.P., Prentice, H.G., Potter, M., Pagliuca, A., Ho, A., Devereux, S., McQuaker, G., Mufti, G., Yin, J.L. & Russell, N.H. (2004) BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood, 103, 428434.
  • Gallamini, A., Zaja, F., Patti, C., Billio, A., Specchia, M.R., Tucci, A., Levis, A., Manna, A., Secondo, V., Rigacci, L., Pinto, A., Iannitto, E., Zoli, V., Torchio, P., Pileri, S. & Tarella, C. (2007) Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood, 110, 23162323.
  • Ginaldi, L., De Martinis, M., Matutes, E., Farahat, N., Morilla, R., Dyer, M.J.S. & Catovsky, D. (1998) Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leukemia Research, 22, 185191.
  • Gupta, V., Ball, S., Yi, Q.L., Sage, D., McCann, S.R., Lawler, M., Ortin, M., Freires, M., Hale, G., Waldmann, H., Gordon-Smith, E.D.C. & Marsh, J.C.W. (2004) Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. Biology of blood and marrow transplantation, 10, 867876.
  • Hale, G., Xia, M.Q., Tighe, H.P., Dyer, M.J.S. & Waldmann, H. (1990) The CAMPATH-1 antigen (CDW52). Tissue Antigens, 35, 118127.
  • Hernandez-Campo, P.M., Almeida, J., Matarraz, S., De Santiago, M., Sanchez, M.L. & Orfao, A. (2007) Quantitative analysis of the expression of glycosylphosphatidylinositol-anchored proteins during the maturation of different hematopoietic cell compartments of normal bone marrow. Cytometry. Part B, Clinical cytometry, 72, 3442.
  • Jaffe, E., Harris, N.L., Stein, H. & Vardiman, J.W. (2001) WHO Classification, Pathology and Genetics Tumors of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France.
  • Keating, M.J., Flinn, I., Jain, V., Binet, J.L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B. & Rai, K.R. (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood, 99, 35543561.
  • Kim, J.G., Sohn, S.K., Chae, Y.S., Cho, Y.Y., Yang, D.H., Lee, J.J., Kim, H.J., Shin, H.J., Chung, J.S., Cho, G.J., Lee, W.S., Joo, Y.D., Sohn, C.H. & Oh, S.J. (2007) Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemotherapy and Pharmacology, 60, 129134.
  • Lundin, J., Hagberg, H., Repp, R., Cavallin-Stahl, E., Freden, S., Juliusson, G., Rosenblad, E., Tjonnfjord, G., Wiklund, T. & Osterborg, A. (2003) Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood, 101, 42674272.
  • Nuckel, H., Frey, U., Roth, A., Duhrsen, U. & Siffert, W. (2005) Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. European Journal of Pharmacology, 514, 217224.
  • Pawson, R., Dyer, M.J.S., Barge, R., Matutes, E., Thornton, P.D., Emmett, E., Kluin-Nelemans, J.C., Fibbe, W.E., Willemze, R. & Catovsky, D. (1997) Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. Journal of Clinical Oncology, 15, 26672672.
  • Piccaluga, P.P., Agnostinelli, C., Righi, S., Zinzani, P.L. & Pileri, S.A. (2007) Expression of CD52 in peripheral T-cell lymphoma. Haematologica, 92, 566567.
  • Rodig, S.J., Abramson, J., Pinkus, G.S., Treon, S.P., Dorfman, D.M., Dong, H.Y., Shipp, M.A. & Kutok, J.L. (2006) Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clinical Cancer Research, 12, 71747179.
  • Thakhi, A., Edinger, M., Myles, J., Pohlman, B. & Tubbs, R.R. (1996) Flow cytometric immunophenotyping of non-Hodgkin’s lymphoma and related disorders. Cytometry, 25, 113124.
  • The Non-Hodgkin’s Lymphoma Classification Project. (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The non-Hodgkin’s lymphoma classification project. Blood, 89, 39093918.
  • Treumann, A., Lifely, M., Schneider, P. & Ferguson, M.A.J. (1995) Primary structure of CD52. Journal of Biological Chemistry, 270, 60886099.
  • Waldmann, H. & Hale, G. (2005) CAMPATH: from concept to clinic. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences, 360, 17071711.
  • Xia, M.Q., Hale, G., Lifely, M.R., Ferguson, M.A.J., Campbell, D., Packman, L. & Waldmann, H. (1993a) Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochemical Journal, 293, 633640.
  • Xia, M.Q., Hale, G. & Waldmann, H. (1993b) Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDW52) antigen. Molecular Immunology, 30, 10891096.
  • Zhang, Z., Zhang, M., Goldman, C.K., Ravetch, J.V. & Waldmann, T.A. (2003) Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Research, 63, 64536457.